Oral medicine

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Retrieved on: 
Thursday, March 14, 2024
Blood pressure, Sinai Hospital, Anaphylaxis, Absorption, Angioedema, Plasma, Type, PD, Patient, Heart rate, Adrenaline, NDA, Epinephrine autoinjector, Cmax, Trial of the century, Mouth, Therapy, Safety, Oral medicine, Allergy, Vomiting, Swelling, FDA, Study, Food, Pharmaceutical industry

“We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.

Key Points: 
  • “We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.
  • “We believe we have a clear understanding of the remaining clinical development steps necessary for a pre-NDA meeting with the FDA in the second half of the year.
  • These latest study results show that the sublingual administration of epinephrine provides rapid and sustained levels of epinephrine similar to approved treatments.
  • The FDA noted that substantial progress had been made in the Anaphylm clinical development program and did not outline any new clinical development requirements.

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Retrieved on: 
Saturday, February 24, 2024
BTK, QPM, BID, AAAAI, Week, Omalizumab, TID, News, Prurigo nodularis, Asthma, Swelling, IgG4-related disease, Skin, Oral medicine, UAS7, Patient, CSU, Disease, Itch, LSM, ITT, American Academy, Pharmaceutical industry

Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.

Key Points: 
  • Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
  • Significant reduction from baseline to week 12 in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20, respectively; p=0.0116].
  • Significant reduction from baseline to week 12 in weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p
  • Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Other Science, Science, Boston, Champaign–Urbana metropolitan area, Health care, University, Multimedia, Hospital, Access, Boston Consulting Group, Molecular biology, Cellular, Oral medicine, Therapy, Patient, Internal medicine, Massachusetts General Hospital, Phase, Harvard Medical School, Nephrology

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.
  • Dr. Becker will serve as a member of the audit committee of the board.
  • View the full release here: https://www.businesswire.com/news/home/20240215803782/en/
    “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan and received his B.S.

Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.

Retrieved on: 
Wednesday, February 14, 2024
Woman, Oral medicine, Alzheimer's disease, NHANES, Pregnancy, National Health, FDA, Dentist, International Academy, Risk, Multiple sclerosis, Safety, Health, Menopause, Parkinson's disease, Patient, DSM-IV codes, Policy, Mercury, Research, Composite, Gold

This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.

Key Points: 
  • This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.
  • In women with amalgam surfaces, the number of surfaces, correlated with significantly higher median daily urinary mercury excretion compared to women without amalgams.
  • Notably, close to 30% of these women received daily mercury vapor doses from amalgams exceeding the safety limits set by the U.S. Environmental Protection Agency.
  • Mercury amalgam dental fillings should be banned by the FDA as they pose a serious risk to the health of all individuals who have amalgam fillings, especially pregnant women and those of reproductive age."

IAOMT Position Paper Examines the Science of Jawbone Cavitations Just Ahead of the Yankee Dental Congress!

Retrieved on: 
Tuesday, January 23, 2024
Patient, Risk, Research, Health, Diagnosis, Dental, International Academy, Oral medicine, Dentistry, Education

The paper is a collaborative effort of renowned experts in the field, aiming to shed light on the diagnosis, risk factors, systemic implications, and treatment modalities associated with jawbone cavitations.

Key Points: 
  • The paper is a collaborative effort of renowned experts in the field, aiming to shed light on the diagnosis, risk factors, systemic implications, and treatment modalities associated with jawbone cavitations.
  • He will be discussing Jawbone Cavitations during his four presentations at the Yankee Dental Congress on January 25th - 27th.
  • "We are excited to release this extensively researched position paper to the dental community," said Dr. Charles Cuprill, President of the IAOMT.
  • Dental professionals, researchers, patients, and other interested parties can access the IAOMT's position paper on Jawbone Cavitations on the organization's official website.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Retrieved on: 
Thursday, December 7, 2023
Sanofi, HS, Inflammation, Disease, Doctor of Philosophy, Therapy, Oral medicine, International development, TPD, Patient, Safety, Pharmaceutical industry

WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi. The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, which generated a $40 million milestone payment under the terms of the collaboration. Study completion dates for both trials are projected in the first quarter of 2025.

Key Points: 
  • The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD.
  • Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023 , which generated a $40 million milestone payment under the terms of the collaboration.
  • Study completion dates for both trials are projected in the first quarter of 2025.
  • “We are pleased to be working with Kymera to explore the potential of IRAK4 degradation to treat a variety of inflammatory conditions, including in our recently initiated Phase 2 AD and HS trials.”

The Inner Circle Acknowledges, Kari Blankenship as a Pinnacle Life Member for her contributions to the Field of Dentistry

Retrieved on: 
Friday, September 22, 2023
Dentistry, University of Texas Health Science Center at San Antonio, Oral medicine, University, Education, Professional, Aesthetics, Hunter College, American Academy, Medicine, Private practice, Science, Inner circle, Field, Dental surgery, Patient, Periodontology, Restaurant, DDS, Dog, MD Anderson Cancer Center, Dental, Family, Michael, Postgraduate training in general dentistry, Mouth, Biscuit, Biology

PLANO, Texas, Sept. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kari Blankenship is acknowledged as a Pinnacle Life Member for her contributions to the Field of Dentistry.

Key Points: 
  • PLANO, Texas, Sept. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kari Blankenship is acknowledged as a Pinnacle Life Member for her contributions to the Field of Dentistry.
  • She finished her formal education and training with rotations at the MD Anderson Cancer Center and gained experience in meeting the needs of medically compromised patients.
  • They provide advice and instruction on taking care of the teeth and gums and on diet choices that affect oral health.
  • She asserts that she has never grown tired of helping people bring out the best that their smiles have to offer.

With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights

Retrieved on: 
Thursday, August 31, 2023
Oral medicine, TNF, Overalls, Sun, Psoriasis, Janssen, Dermatology, Patient, RealTime, Skin, Safety, Pharmaceutical industry, Deucravacitinib

With the entry of each next generation biologic, the standards of care and expected bar of performance have continually expanded.

Key Points: 
  • With the entry of each next generation biologic, the standards of care and expected bar of performance have continually expanded.
  • In fact, US dermatologists in Spherix Global Insights’ RealTime Dynamix™: Plaque Psoriasis Q3 update estimate overall patient share for the legacy oral asset is nearly double that of Sotyktu.
  • When probed specifically on what, if any, remaining needs exist, it is clear the future is oral.
  • Spherix also captured where in the treatment algorithm assets such as JNJ-2113 would fit and will continue to track the evolving pipeline opportunities via it’s RealTime Dynamix™: Plaque Psoriasis service.

The Inner Circle Acknowledges, Dr. Jessalyn Forrella, DDS as a Top Pinnacle Professional for her contributions to the field of Dentistry

Retrieved on: 
Tuesday, August 29, 2023
American Dental Association, Cosmetic dentistry, University, Oral medicine, Koi, Education, American Academy of Cosmetic Dentistry, Dentist, Overalls, Quality of life, Rehabilitation, Multimedia, University college, Jacobi Medical Center, Inner circle, Organization, Philosophy, Dental surgery, Patient, New York University College of Dentistry, DDS, Exotic Feline Rescue Center, Reading, Dental care, Knowledge, Postgraduate training in general dentistry, Align Technology, Dental, Dentistry, Neuroscience, Chemistry

FAIRFIELD, Conn., Aug. 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Jessalyn Forrella, DDS is a Top Pinnacle Professional for her contributions to the field of Dentistry.

Key Points: 
  • FAIRFIELD, Conn., Aug. 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Jessalyn Forrella, DDS is a Top Pinnacle Professional for her contributions to the field of Dentistry.
  • Dedicated to providing the latest innovations to her patients, she furthered her expertise in biomimetic dentistry through additional training at the Koi's Center.
  • Dentists play a crucial role in diagnosing and addressing dental problems while assisting patients in improving their oral hygiene practices.
  • Dr. Forella has been happily married to Mr. Scott Axtell for one year, and their relationship has spanned 11 years.

The Inner Circle Acknowledges, Robert Wunsc as a Top Pinnacle Healthcare Professional for his contributions to the field of Dentistry

Retrieved on: 
Friday, August 25, 2023
Oral medicine, Wyomissing Area Junior/Senior High School, Education, Dentist, AGD, Hockey, Albright College, Best, Medicine, Multimedia, Diagnosis: Murder, Inner circle, Pennsylvania Magazine of History and Biography, Philosophy, Community, Patient, Love, Reading, Physical fitness, Diagnosis, Postgraduate training in general dentistry, Mouth, Dentistry

WYOMISSING, Pa., Aug. 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Robert Wunsch is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Dentistry.

Key Points: 
  • WYOMISSING, Pa., Aug. 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Robert Wunsch is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Dentistry.
  • He pursued higher education at Albright College and continued competing at the collegiate level.
  • The doctor then attended Temple University Maurice H. Kornberg School of Dentistry in 1991 and completed a residency at Community General Hospital from 1991 until 1992.
  • Dentists like Dr. Wunsch and his team, diagnose and treat dental issues and help patients develop better oral hygiene regimens.